Nathalie Adda - Apr 1, 2022 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Sr. VP & Chief Medical Officer
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Apr 1, 2022
Transactions value $
-$2,581,242
Form type
4
Date filed
4/5/2022, 07:54 PM
Previous filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Options Exercise $503K +16K +45.74% $31.42 51K Apr 1, 2022 Direct
transaction ENTA Common Stock Options Exercise $950K +31.7K +62.11% $30.00 82.6K Apr 1, 2022 Direct
transaction ENTA Common Stock Options Exercise $140K +2.9K +3.5% $48.52 85.5K Apr 1, 2022 Direct
transaction ENTA Common Stock Sale -$587K -8.3K -9.7% $70.75 77.2K Apr 1, 2022 Direct F1, F2
transaction ENTA Common Stock Sale -$3.01M -42.3K -54.71% $71.32 35K Apr 1, 2022 Direct F1, F3
transaction ENTA Common Stock Options Exercise $305K +6.29K +17.97% $48.52 41.3K Apr 4, 2022 Direct
transaction ENTA Common Stock Options Exercise $419K +9.63K +23.32% $43.57 50.9K Apr 4, 2022 Direct
transaction ENTA Common Stock Options Exercise $1.07M +16.9K +33.16% $63.35 67.8K Apr 4, 2022 Direct
transaction ENTA Common Stock Sale -$176K -2.5K -3.69% $70.56 65.3K Apr 4, 2022 Direct F1, F4
transaction ENTA Common Stock Sale -$1.3M -18.1K -27.7% $71.71 47.2K Apr 4, 2022 Direct F1, F5
transaction ENTA Common Stock Sale -$232K -3.2K -6.78% $72.65 44K Apr 4, 2022 Direct F1, F6
transaction ENTA Common Stock Sale -$661K -9.01K -20.48% $73.42 35K Apr 4, 2022 Direct F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -16K -100% $0.00* 0 Apr 1, 2022 Common Stock 16K $31.42 Direct F8
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -31.7K -100% $0.00* 0 Apr 1, 2022 Common Stock 31.7K $30.00 Direct F8
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -2.9K -31.54% $0.00 6.29K Apr 1, 2022 Common Stock 2.9K $48.52 Direct F8
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -6.29K -100% $0.00* 0 Apr 4, 2022 Common Stock 6.29K $48.52 Direct F8
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -9.63K -31.25% $0.00 21.2K Apr 4, 2022 Common Stock 9.63K $43.57 Direct F9
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -16.9K -56.25% $0.00 13.1K Apr 4, 2022 Common Stock 16.9K $63.35 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.12 to $71.00, inclusive.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.02 to $72.00, inclusive.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.06 to $70.99, inclusive.
F5 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive.
F6 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99, inclusive.
F7 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.91, inclusive.
F8 100% of the shares subject to the option are fully vested and exercisable.
F9 The option, representing a right to purchase a total of 30,800 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020).
F10 The option, representing a right to purchase a total of 30,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019).

Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7 above.